What is Gyre Therapeutics, Inc.'s EV / EBITDA?

Gyre Therapeutics, Inc. (GYRE) reported EV / EBITDA of 66.1× in Q4 2025.

How has Gyre Therapeutics, Inc.'s EV / EBITDA changed year-over-year?

Gyre Therapeutics, Inc.'s EV / EBITDA increased by 13.9% year-over-year, from 58.1× to 66.1×.

What does EV / EBITDA mean?

Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Gyre Therapeutics, Inc. (GYRE) EV / EBITDA

Screener

EV / EBITDA at other companies

Eli LillyLLY

31.3×-7.9×

Theravance BiopharmaTBPH

199.8×—

Rigel PharmaceuticalsRIGL

4.3×-1.7×

Zevra Therapeutics, Inc.ZVRA

7.9×—

Innoviva, Inc.INVA

7.3×+0.6×

Ligand PharmaceuticalsLGND

50.6×-3,379×

Other financials

Income statement

See full

Revenue$29.1M-2.1%

Gross profit$26.9M-5.9%

Operating income-$14.4M-541%

Net income-$11.7M-471%

EPS (diluted)-$0.12-300%

Balance sheet

See full

Cash & equivalents$43.3M+18.6%

Total debt$3.4M+145%

Total equity$107.9M+17.3%

Total assets$199.3M+30.5%

Cash flow

See full

Operating cash flow-$16.7M-124%

CapEx$262.0K-21.8%

Free cash flow-$17.0M-118%

Valuation

See full

Market cap$743.63M+16.0%

Enterprise value$703.76M+16.2%

P/S6.2×+0.1×

Profitability

See full

Gross margin94.3%-1.7pp

Operating margin-14%-18.7pp

Net margin-13.4%-15.1pp

FCF margin-5.1%—

Returns & leverage

See full

Return on equity-16%-18.3pp

Debt / equity0×0.0×

Current ratio4.3×-1.1×

Where this comes from

Calculated from Gyre Therapeutics, Inc.’s reported figures.

enterprise value/ebitda=66.1×

Based on the most recent quarter.

The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026. Open the filing →

Filed: Aug 7, 2026, 5:00 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001193125-26-340448

FAQ

What is Gyre Therapeutics, Inc.'s EV / EBITDA?: Gyre Therapeutics, Inc. (GYRE) reported EV / EBITDA of 66.1× in Q4 2025.
How has Gyre Therapeutics, Inc.'s EV / EBITDA changed year-over-year?: Gyre Therapeutics, Inc.'s EV / EBITDA increased by 13.9% year-over-year, from 58.1× to 66.1×.
What does EV / EBITDA mean?: Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Ask your AI about Gyre Therapeutics, Inc.'s ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Gyre Therapeutics, Inc. GYRE EV / EBITDA

EV / EBITDA at other companies

Other financials

Income statement

Balance sheet

Cash flow

Valuation

Profitability

Returns & leverage

Where this comes from

FAQ

Ask your AI about Gyre Therapeutics, Inc.'s ev / ebitda.